DK2897611T3 - Fremgangsmåder til behandling af hepatitis c - Google Patents

Fremgangsmåder til behandling af hepatitis c Download PDF

Info

Publication number
DK2897611T3
DK2897611T3 DK13773463T DK13773463T DK2897611T3 DK 2897611 T3 DK2897611 T3 DK 2897611T3 DK 13773463 T DK13773463 T DK 13773463T DK 13773463 T DK13773463 T DK 13773463T DK 2897611 T3 DK2897611 T3 DK 2897611T3
Authority
DK
Denmark
Prior art keywords
methods
treating hepatitis
hepatitis
treating
Prior art date
Application number
DK13773463T
Other languages
English (en)
Inventor
Teresa Ng (lok-Chan)
Tami J Pilot-Matias
Warren M Kati
Preethi Krishnan
Clarence J Maring
Neeta C Mistry
Thomas J Reisch
Rolf Wagner
John K Pratt
Mark A Matulenko
Ryan G Keddy
Dachun Liu
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2897611(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Application granted granted Critical
Publication of DK2897611T3 publication Critical patent/DK2897611T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK13773463T 2012-09-18 2013-09-17 Fremgangsmåder til behandling af hepatitis c DK2897611T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702564P 2012-09-18 2012-09-18
PCT/US2013/060103 WO2014047039A1 (en) 2012-09-18 2013-09-17 Methods for treating hepatitis c

Publications (1)

Publication Number Publication Date
DK2897611T3 true DK2897611T3 (da) 2019-11-04

Family

ID=49304326

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13773463T DK2897611T3 (da) 2012-09-18 2013-09-17 Fremgangsmåder til behandling af hepatitis c

Country Status (25)

Country Link
US (1) US20140080868A1 (da)
EP (2) EP3597190A1 (da)
JP (4) JP6297044B2 (da)
CN (1) CN104797253A (da)
AU (2) AU2013318302B2 (da)
BR (1) BR112015006037B1 (da)
CA (1) CA2884539C (da)
CY (1) CY1122442T1 (da)
DK (1) DK2897611T3 (da)
ES (1) ES2755089T3 (da)
HR (1) HRP20191939T1 (da)
HU (1) HUE046544T2 (da)
LT (1) LT2897611T (da)
MX (2) MX367796B (da)
NZ (1) NZ630581A (da)
PL (1) PL2897611T3 (da)
PT (1) PT2897611T (da)
RS (1) RS59640B1 (da)
RU (1) RU2665365C2 (da)
SG (2) SG10201702248UA (da)
SI (1) SI2897611T1 (da)
SM (1) SMT201900683T1 (da)
TW (1) TWI621436B (da)
WO (1) WO2014047039A1 (da)
ZA (1) ZA201501752B (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2897611T3 (pl) * 2012-09-18 2020-03-31 Abbvie Inc. Sposób leczenia wirusowego zapalenia wątroby typu C
WO2015153792A1 (en) * 2014-04-02 2015-10-08 Abbvie Inc. Methods for treating hcv
KR20210013344A (ko) * 2013-03-14 2021-02-03 애브비 인코포레이티드 C형 간염 치료용 2가지 항바이러스제의 병용물
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
US10286029B2 (en) 2013-03-14 2019-05-14 Abbvie Inc. Method for treating HCV
RU2018102809A (ru) * 2015-06-26 2019-07-29 Эббви Инк. Твердые фармацевтические композиции для лечения вируса гепатита с
US20160375017A1 (en) 2015-06-26 2016-12-29 Abbvie Inc. Solid Pharmaceutical Compositions for Treating HCV
JP6808660B2 (ja) * 2015-07-08 2021-01-06 アッヴィ・インコーポレイテッド Hcvを処置するための方法
CR20180088A (es) * 2015-07-17 2018-05-24 Abbvie Inc Composiciones farmacéuticas sólidas para el tratamiento del vhc
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
CA3203975A1 (en) 2020-12-03 2022-06-09 Battelle Memorial Institute Polymer nanoparticle and dna nanostructure compositions and methods for non-viral delivery
CA3216359A1 (en) 2021-04-07 2022-10-13 Battelle Memorial Institute Rapid design, build, test, and learn technologies for identifying and using non-viral carriers
GB202113944D0 (en) * 2021-09-29 2021-11-10 Univ Liverpool Injectable formulations
AU2024353375A1 (en) 2023-09-29 2026-04-09 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025122954A1 (en) 2023-12-08 2025-06-12 Battelle Memorial Institute Use of dna origami nanostructures for molecular information based data storage systems

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008010355A (es) * 2006-02-09 2008-10-31 Schering Corp Combinaciones que comprenden inhibidores de proteasa del virus de la hepatitis c e inhibidores de polimerasa del virus de la hepatitis c, y metodos de tratamiento relacionados con los mismos.
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
US8937150B2 (en) * 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
DE202012012955U1 (de) * 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
PL2897611T3 (pl) * 2012-09-18 2020-03-31 Abbvie Inc. Sposób leczenia wirusowego zapalenia wątroby typu C

Also Published As

Publication number Publication date
JP6297044B2 (ja) 2018-03-20
SI2897611T1 (sl) 2019-12-31
TWI621436B (zh) 2018-04-21
RU2015114543A (ru) 2016-11-10
MX367796B (es) 2019-09-06
ES2755089T3 (es) 2020-04-21
HRP20191939T1 (hr) 2020-01-10
BR112015006037B1 (pt) 2022-05-17
JP2021054849A (ja) 2021-04-08
RU2665365C2 (ru) 2018-08-29
TW201412311A (zh) 2014-04-01
AU2018203608B2 (en) 2019-12-19
US20140080868A1 (en) 2014-03-20
BR112015006037A2 (pt) 2017-07-04
AU2018203608A1 (en) 2018-06-14
HK1209319A1 (en) 2016-04-01
EP2897611B1 (en) 2019-07-24
EP3597190A1 (en) 2020-01-22
PT2897611T (pt) 2019-11-27
AU2013318302B2 (en) 2018-02-22
AU2013318302A1 (en) 2015-04-02
CA2884539C (en) 2022-06-21
JP2019194241A (ja) 2019-11-07
EP2897611A1 (en) 2015-07-29
CA2884539A1 (en) 2014-03-27
JP2015528511A (ja) 2015-09-28
WO2014047039A1 (en) 2014-03-27
MX2019010600A (es) 2020-02-03
CY1122442T1 (el) 2021-01-27
JP6556884B2 (ja) 2019-08-07
MX2015003501A (es) 2015-10-26
PL2897611T3 (pl) 2020-03-31
CN104797253A (zh) 2015-07-22
JP2018109035A (ja) 2018-07-12
HUE046544T2 (hu) 2020-03-30
NZ630581A (en) 2017-02-24
LT2897611T (lt) 2019-12-10
SG11201502095SA (en) 2015-05-28
ZA201501752B (en) 2016-08-31
RS59640B1 (sr) 2020-01-31
SG10201702248UA (en) 2017-04-27
SMT201900683T1 (it) 2020-01-14

Similar Documents

Publication Publication Date Title
IL269662A (en) Hepatitis C virus inhibitors
DK2897611T3 (da) Fremgangsmåder til behandling af hepatitis c
DK2709613T4 (da) Fremgangsmåder til behandling af hcv
DK2906696T4 (da) Fremgangsmåder til modulering af c9orf72-ekspression
DK2885010T3 (da) Fremgangsmåder til behandling med tauopati
DK2906698T3 (da) Fremgangsmåde til behandling af alports syndrom
DK2968208T3 (da) Behandling af kataplexi
DK2897620T3 (da) Fremgangsmåde til behandling af cancer
DK3454346T3 (da) Anordning til cylotronfremstilling af technetium-99m
DK3461895T3 (da) Modulation af ube3a-ats-ekspression
DK2854769T3 (da) Fremgangsmåder til behandling af artritis
DK3412687T3 (da) Fremgangsmåder til behandling af dlbcl
DK3626270T3 (da) Behandling af kardiovaskulære sygdomme
DK2961378T3 (da) Fremgangsmåder til behandlingen af mitochondrisk sygdom
DK2857019T3 (da) Fremgangsmåde til behandling af multipel sklerose
DK3581199T3 (da) Fremgangsmåder til behandling eller reduktion af ødematøs fibrosklerotisk pannikulitis
DK2836460T3 (da) Fremgangsmåde til fremstilling af graphen
DK2705847T3 (da) Sammensætning til behandling af psoriasis
DK2701707T3 (da) Fremgangsmåde til behandling af dyskinesi
DK2888228T3 (da) Inhibitorer af CD40-TRAF6 interaktion
DK2901162T3 (da) Fremgangsmåde til diagnosticering af muskeldystrofi
DK2847363T3 (da) Fremgangsmåde til påføring af metal
DK2838850T3 (da) Oprensning af titantetrachlorid
DK2481821T3 (da) Fremgangsmåde til behandling af læder
DK2948143T3 (da) Anvendelse af phenoxypropylaminforbindelser til behandling af depression